BRPI0412459A - composto tendo ação anti-hcv e seu método de produção - Google Patents

composto tendo ação anti-hcv e seu método de produção

Info

Publication number
BRPI0412459A
BRPI0412459A BRPI0412459-6A BRPI0412459A BRPI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A
Authority
BR
Brazil
Prior art keywords
compound
hcv
production
production method
bond
Prior art date
Application number
BRPI0412459-6A
Other languages
English (en)
Inventor
Masayuki Sudoh
Takuo Tsukuda
Miyako Masubuchi
Kenichi Kawasaki
Takeshi Murata
Fumio Watanabe
Hiroshi Fukuda
Susumu Komiyama
Tadakatsu Hayase
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0412459A publication Critical patent/BRPI0412459A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO TENDO AçãO ANTI-HCV E SEU MéTODO DE PRODUçãO". O objetivo da presente invenção é fornecer um composto útil para a prevenção e tratamento de doenças infecciosas virais, e particularmente doenças do fígado causadas pela infecção por HCV, devido a isto tendo um grau elevado de atividade inibidora da replicação contra o HCV, seu método de produção, um composto intermediário útil para a sua produção e uma composição farmacêutica contendo estes compostos, e a presente invenção diz respeito a um composto representado pela fórmula (I) (em que A representa -(CH~ 2~)~ n~-, etc.; B representa -(C=O)-, etc.; D representa (CH~ 2~)~ m~-R<39>, etc.; E representa um átomo de hidrogênio, etc.; G representa (CH~ 2~)~ p~-J, etc.; a ligação Q representa uma ligação única ou ligação dupla; e R~ 1~, R~ 2~ e R~ 3~ podem ser os mesmos ou diferentes e cada um representa um átomo de hidrogênio, etc.), um pró-medicamento deste ou um sal farmaceuticamente aceitável deste.
BRPI0412459-6A 2003-07-09 2004-07-09 composto tendo ação anti-hcv e seu método de produção BRPI0412459A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003272420 2003-07-09
PCT/JP2004/009803 WO2005005372A1 (ja) 2003-07-09 2004-07-09 抗hcv作用を有する化合物およびその製法

Publications (1)

Publication Number Publication Date
BRPI0412459A true BRPI0412459A (pt) 2006-10-17

Family

ID=34055974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412459-6A BRPI0412459A (pt) 2003-07-09 2004-07-09 composto tendo ação anti-hcv e seu método de produção

Country Status (17)

Country Link
US (1) US7378446B2 (pt)
EP (1) EP1661882B1 (pt)
JP (1) JP4068639B2 (pt)
KR (1) KR20060029182A (pt)
CN (1) CN1819990B (pt)
AU (1) AU2004255633B2 (pt)
BR (1) BRPI0412459A (pt)
CA (1) CA2531790A1 (pt)
IL (1) IL172666A0 (pt)
MX (1) MXPA06000294A (pt)
MY (1) MY143775A (pt)
NO (1) NO20055986L (pt)
NZ (1) NZ545102A (pt)
RU (1) RU2346933C2 (pt)
TW (1) TWI330173B (pt)
UA (1) UA92134C2 (pt)
WO (1) WO2005005372A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183005B1 (en) 2004-08-11 2012-05-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agents for treating HCV infections
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗hcv作用を有する化合物およびそれを含む医薬組成物
WO2006088071A1 (ja) * 2005-02-17 2006-08-24 Chugai Seiyaku Kabushiki Kaisha 抗hcv作用を有する化合物の製造方法およびその中間体
US20110098477A1 (en) * 2005-06-28 2011-04-28 Chugai Seiyaku Kabushiki Kaisha Method Of Producing Compound Having Anti-Hcv Activity
JP2009516730A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ L−アラニン誘導体
AU2007250739A1 (en) 2006-05-16 2007-11-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing HCV infection
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8957199B2 (en) 2008-11-26 2015-02-17 Chugai Seiyaku Kabushiki Kaisha Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
JPWO2014027696A1 (ja) 2012-08-17 2016-07-28 中外製薬株式会社 抗hcv作用を有する経口投与可能なビリジオファンジン誘導体
JP7565930B2 (ja) * 2019-08-23 2024-10-11 パナソニックホールディングス株式会社 支援装置、分析装置、支援方法、分析方法、およびプログラム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5364948A (en) 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
DE4415312A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Verfahren zur Herstellung von N-Acylglycinderivaten
AU7552098A (en) * 1997-06-09 1998-12-30 Takara Shuzo Co., Ltd. Physiologically active substances tkr2449, process for producing the same, and microorganism
JP5025051B2 (ja) 2001-07-26 2012-09-12 サトーホールディングス株式会社 印字編集処理装置
JP4093534B2 (ja) 2002-03-15 2008-06-04 スタンレー電気株式会社 車両用前照灯
MY141506A (en) 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug

Also Published As

Publication number Publication date
EP1661882A4 (en) 2007-01-31
AU2004255633B2 (en) 2009-08-06
MXPA06000294A (es) 2006-04-18
EP1661882B1 (en) 2013-10-30
JPWO2005005372A1 (ja) 2006-08-24
CN1819990A (zh) 2006-08-16
CA2531790A1 (en) 2005-01-20
HK1093485A1 (zh) 2007-03-02
TW200524847A (en) 2005-08-01
NZ545102A (en) 2008-11-28
RU2006103803A (ru) 2006-08-10
US20060194870A1 (en) 2006-08-31
EP1661882A1 (en) 2006-05-31
UA92134C2 (ru) 2010-10-11
AU2004255633A1 (en) 2005-01-20
KR20060029182A (ko) 2006-04-04
NO20055986L (no) 2006-02-13
CN1819990B (zh) 2010-04-21
IL172666A0 (en) 2006-04-10
US7378446B2 (en) 2008-05-27
JP4068639B2 (ja) 2008-03-26
WO2005005372A1 (ja) 2005-01-20
TWI330173B (en) 2010-09-11
MY143775A (en) 2011-07-15
RU2346933C2 (ru) 2009-02-20

Similar Documents

Publication Publication Date Title
BRPI0412459A (pt) composto tendo ação anti-hcv e seu método de produção
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2006122011A3 (en) Thiazole compounds and methods of use
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
BR0313694A (pt) Derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BR0314314A (pt) Derivados do éter 4-pirrolidina-fenil-benzìlico
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
BRPI0515851A (pt) composto de pirimidona
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
BRPI0408295A (pt) uso de um composto
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
AU2018319549C1 (en) Compositions and methods for ameliorating pain
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.